Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 718 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: current standard of care treatments Clear all

Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions: CP101; Biological
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more

Conditions: Chronic Low-back Pain
Interventions: Flowly (TMC-CP01); Device
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
Interventions: genotype-directed dosing with dosing software based on therapeutic drug monitoring; Other
Lead sponsor: The University of Queensland; Other
Eligibility: 2 Years and older
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Tobacco Cessation
Interventions: Tailored behavioral counseling, Tobacco cessation pharmacotherapy; Behavioral · Drug
Lead sponsor: Iowa City Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Persistent Atrial Fibrillation
Interventions: Scar-Based Radio-frequency Ablation, Rotor Anchors Radio-frequency Ablation, Conventional PVI by Radio-frequency Ablation; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urothelial Carcinoma Bladder
Interventions: Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion; Drug · Radiation · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Burns, Contracture Scar, Surgical Injury
Interventions: Split Thickness Skin Graft (STSG), Base of wound fat graft with STSG Reconstruction (Autologous Layered Composite Grafting).; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Effect of Drug
Interventions: Bupivacaine Injection; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: Up to 89 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Status Asthmaticus
Interventions: preservative free albuterol; Drug
Lead sponsor: Norton Healthcare; Other
Eligibility: 5 Years to 17 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions: Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia

Conditions: Colorectal Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: Harbinger Health; Industry
Eligibility: 45 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 9 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Asthma
Interventions: Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 46
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Esophageal Motility Disorders
Interventions: Per-oral Endoscopic Myotomy, Speedboat (Bipolar electrocautery knife); Procedure · Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebral Palsy, Neurologic Disorder, Chromosome Abnormality, Spina Bifida
Interventions: Lite Run Gait Trainer, Usual Treatments; Device · Other
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 4 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes
Interventions: Automated insulin delivery (AID) system, Intravenous (IV) insulin; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • San Francisco, California

Conditions: Extracorporeal Membrane Oxygenation
Interventions: Fresh frozen plasma; Biological
Lead sponsor: Duke University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Treatment-resistant Schizophrenia
Interventions: Evenamide 15 mg bid, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: Hypertension
Interventions: optima4BP; Other
Lead sponsor: Optima Integrated Health; Industry
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smoking, Smoking Cessation
Interventions: Coordinated Care, Usual Care; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Concussion, Brain, Sleep Disorder
Interventions: Brief Sleep Intervention; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Opioid Use Disorder, Dual Diagnosis, Housing Problems, Mental Disorder in Adolescence, Risk Behavior, Homelessness
Interventions: Motivational Interviewing/Community Reinforcement Approach (MI/CRA), Strengths-Based Outreach and Advocacy (SBOA ), Services as Usual (SAU); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 14 Years to 24 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Acute Coronary Syndrome, Depression
Interventions: Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care; Behavioral · Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more

Conditions: Von Willebrand Disease, Type 3
Interventions: Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Month and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more

Search by objective public record fields.

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

VANISH for Chronic Low Back Pain

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

A Stepped Care Approach to Treating Tobacco Use in Rural Veterans

The Substrate and Intervention Mechanisms for Persistent Atrial Fibrillation Trial

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Autologous Point-of-Care Adipose Therapy: Recent Injury

Marcaine Post-Operative Pain Study

Comparison of Albuterol for Status Asthmaticus

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study

Twice Weekly Steroids and Exercise as Therapy for DMD

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

Monopolar and Bipolar Current RFA Knife in POEM

Post-operative Lite Run Study

Automated Insulin for Management of Intrapartum Glycemia

The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Tailored Drug Titration Through Artificial Intelligence

Connect to Quit for Smoking

Addressing Sleep in Adolescents Post-Concussion ("ASAP Study")

Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness

Comparison of Depression Interventions After Acute Coronary Syndrome

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease